Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Fludarabine is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of fludarabine in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that clinical and genetic factors cause changes in fludarabine drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.
| Condition |
|---|
|
Hematologic Malignancies Nonmalignant Diseases Immunodeficiencies Hemoglobinopathies Genetic Inborn Errors of Metabolism Fanconi's Anemia, Thalassemia Sickle Cell Disease |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Population Pharmacokinetics of Fludarabine in Pediatric Patients Undergoing Hematopoietic Cell Transplantation |
- Identify specific clinical markers or characteristics that impact fludarabine PK exposure. [ Time Frame: up to 100 days post transplant ] [ Designated as safety issue: No ]
- Establish the relationship between fludarabine exposure and clinical outcomes. [ Time Frame: up to 100 days post transplant ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
whole blood, DNA
| Estimated Enrollment: | 45 |
| Study Start Date: | September 2010 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
Fludarabine is a nucleoside analog with potent antitumor and immunosuppressive properties used in conditioning regimens of pediatric allogeneic hematopoietic cell transplantation (alloHCT) to promote stem cell engraftment.
This is a single-center, pharmacokinetic-pharmacodynamic (PK-PD) study investigating the clinical pharmacology of fludarabine in 45 children undergoing alloHCT at UCSF Benioff Children's Hospital.
Patients would receive fludarabine regardless of whether or not they decide to consent to PK sampling.
Fludarabine doses will not be adjusted based on PK data.
We will apply the combination of a D-optimality-based limited sampling strategy and population PK methodologies to determine specific factors influencing fludarabine exposure in pediatric alloHCT recipients and identify exposure-response relationships.
Subjects will undergo PK sampling of plasma (f-ara-a) and intracellular (f-ara-ATP) drug concentrations over the duration of fludarabine therapy (3 to 5 days).
To evaluate sources of variability impacting fludarabine exposure clinical data will be obtained from the patient's medical chart on each day of PK sampling.
A single blood draw for the collection of DNA and genotyping of single nucleotide polymorphisms of genes involved in fludarabine activation, transport or elimination will occur in all patients.
To assess exposure-response relationships neutrophil engraftment, treatment-related toxicity, and survival data will be collected through day 100 post-transplant.
Eligibility| Ages Eligible for Study: | up to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
The target population for the proposed study includes children 0-17 years of age undergoing alloHCT for the treatment of malignant and nonmalignant disorders.
Patients receiving fludarabine over 3 to 5 days are eligible to participate.
All patients enrolled in this study will undergo PK sampling on the inpatient pediatric BMT unit at UCSF Benioff Children's Hospital. The proposed research will not study any patients receiving fludarabine in a clinic or any other out-patient setting.
Inclusion Criteria:
- Children 0-17 years of age
- Undergoing alloHCT for the treatment of malignant or nonmalignant disorder
- Receiving fludarabine-based preparative regimen
Exclusion Criteria:
- Any child 7-17 years of age unwilling to provide assent
- Parent or guardian unwilling to provide written consent
Contacts and Locations| Contact: Janel R Long-Boyle, PharmD, PhD | 415-514-2746 | long-boylej@pharmacy.ucsf.edu |
| Contact: Chris Dvorak, MD | 415-476-0554 | dvorakc@peds.ucsf.edu |
| United States, California | |
| University of California, San Francisco | Recruiting |
| San Francisco, California, United States, 94143 | |
| Contact: Janel R Long-Boyle, PharmD, PhD 415-514-2746 long-boylej@pharmacy.ucsf.edu | |
| Principal Investigator: Janel R Long-Boyle, PharmD, PhD | |
| Principal Investigator: | Janel R Long-Boyle, PharmD, PhD | University of California, San Francisco |
More Information
No publications provided
| Responsible Party: | University of California, San Francisco |
| ClinicalTrials.gov Identifier: | NCT01316549 History of Changes |
| Other Study ID Numbers: | P0037192 |
| Study First Received: | March 14, 2011 |
| Last Updated: | September 24, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of California, San Francisco:
|
fludarabine pharmacokinetics pediatric allogeneic hematopoietic cell transplantation |
Additional relevant MeSH terms:
|
Anemia Anemia, Sickle Cell Neoplasms Fanconi Anemia Fanconi Syndrome Hemoglobinopathies Immunologic Deficiency Syndromes Metabolism, Inborn Errors Thalassemia Hematologic Neoplasms Hematologic Diseases Anemia, Hemolytic, Congenital Anemia, Hemolytic Genetic Diseases, Inborn Anemia, Hypoplastic, Congenital |
Anemia, Aplastic Bone Marrow Diseases DNA Repair-Deficiency Disorders Metabolic Diseases Kidney Diseases Urologic Diseases Renal Tubular Transport, Inborn Errors Immune System Diseases Neoplasms by Site Fludarabine Fludarabine monophosphate Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Immunosuppressive Agents |
ClinicalTrials.gov processed this record on May 23, 2013